CYTO Altamira Therapeutics Ltd

25,721

$0.2445

$0.0095

(4.04%)

Today

Watchers	25,721
52-Wk Low	$0.22
52-Wk High	$13.52

Market Cap	$2.16M
Volume (M)	230,630.00
52-Wk High	$13.52
52-Wk Low	$0.22

Fundamentals

Altamira Therapeutics Reports Additional Significant Efficacy Outcomes from Bentrio Clinical Trial in Seasonal Allergic RhinitisGlobe Newswire • 17 days ago

HAMILTON, BERMUDA , Sept. 14, 2023 (GLOBE NEWSWIRE) -- Fresh data from randomized controlled NASAR clinical trial further demonstrate efficacy and tolerability of Bentrio nasal spray in...

Share to Feed

Altamira Therapeutics reports 1H of 2023 revenue CHF 0.1M vs CHF0.3M last yearThe Fly • 19 days ago

See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Altamira Therapeutics Provides Business Update and First Half 2023 Financial ResultsGlobe Newswire • 19 days ago

HAMILTON, BERMUDA, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Company hosts 1H 2023 Financial Results and Business Update call today at 8 a.m. ET First research collaboration with biopharmaceutical...

Altamira Therapeutics Ltd. (CYTO) Q2 2023 Earnings Call TranscriptSeekingAlpha • 19 days ago

Altamira Therapeutics Ltd. (CYTO) Q2 2023 Earnings Call Transcript...

Altamira Therapeutics to Host First Half 2023 Financial Results and Business Update Call on September 12thGlobe Newswire • 25 days ago

HAMILTON, BERMUDA , Sept. 06, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important...

Altamira Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13Globe Newswire • about 1 month ago

HAMILTON, BERMUDA, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that its founder, Chairman, and CEO Thomas Meyer will be presenting...

Altamira Therapeutics and Pharma Nordic Collaborate for Marketing and Distribution of Bentrio in ScandinaviaGlobe Newswire • 2 months ago

HAMILTON, BERMUDA, July 20, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important...

Altamira Therapeutics Announces Publication of Positive Results from Clinical Trial with Bentrio in House Dust Mite Allergy in Leading Peer Reviewed JournalGlobe Newswire • 3 months ago

HAMILTON, BERMUDA, July 17, 2023 (GLOBE NEWSWIRE) -- -Detailed results from house dust mite trial published in Clinical and Translational Allergy-Study demonstrates statistically significant alleviation of nasal symptoms of allergic rhinitis Altamira Therapeutics Ltd. ("Altamira" or the "Company") (...

Why Altamira Therapeutics (CYTO) Stock Is Getting HammeredBenzinga • 3 months ago

Altamira Therapeutics Ltd (NASDAQ: CYTO)shares are trading lower by 19.23% to $0.44 Thursday morning after the company announced pricing of a $5 million public offer read more...